FDA approves landmark pancreatic cancer drug

Blue pills — The drug costs $39,800 for a 30-day supply

(Image credit: Vlad Vulturar / iStock / Getty Images Plus)

What happened

The Food and Drug Administration on Wednesday approved a first-of-its-kind drug for advanced pancreatic cancer, one of the deadliest types of cancer and among the hardest to treat. The FDA’s expedited approval of daraxonrasib, a daily pill developed by Revolution Medicines and sold as Rasonque, followed a clinical trial in which patients on the drug lived a median 13.2 months, twice as long as those who underwent chemotherapy, and with fewer side effects. Some “patients who have gotten the drug through clinical trials have lived for years,” The New York Times said.

Daraxonrasib has “electrified cancer specialists and patients,” the Times said. It’s “not a cure, but it is the first treatment to substantially extend the lives of patients” with a disease long considered among the “most hopeless in medicine.” Nearly all pancreatic tumors are fueled by a mutated cellular protein, KRAS, that’s stubbornly resistant to interventions. Daraxonrasib “uses what’s essentially a molecular glue to bind with multiple KRAS subtypes” and shut them down, The Associated Press said. Revolution is “studying its technology for several other forms of cancer, including lung cancer.”